-
2024-514637-37-00
5
2020-02-11
Patients with bone sarcomas other than chordoma, who have no residual
-
2023-508072-11-00
5
2019-06-26
Castration-resistant prostate cancer
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-516704-41-00
11
2016-03-30
Rheumatoid Arthritis
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2024-511882-13-01
5
2024-11-19
Cardiac failure
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2024-517024-20-00
9
2022-09-27
Metastatic colorectal cancer patients
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2024-511658-28-01
5
2021-04-06
primary sclerosing cholangitis
-
2023-503380-42-00
6
2020-11-16
patient with moderate to severe Crohn's disease
with at least one acti
-
2024-515331-30-00
7
2020-10-30
Primary Central Nervous System Lymphoma (PCNSL)
-
2024-513005-31-00
5
2020-06-11
Patients with untreated metastatic Estrogen Receptor positive (ER+), H
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2024-513728-40-00
5
2019-07-02
scheduled surgery for digestive cancer
-
2024-516048-24-00
4
2019-06-19
CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST
-
2023-505286-84-00
4
2018-06-25
Pancreatic well differentiated neuroendocrine tumors (NET)
-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2023-509322-22-00
4
2025-11-26
localized colon cancer